GILD Gilead Sciences Inc
Company Analysis
Latest News
Gilead's Oral Colitis Drug Beats Placebo in Phase 2 Trial
Gilead Sciences reported positive results from the Phase 2 SWIFT study of emvistegrast, an experimental once-daily oral pill for moderate to severe ulcerative...
Gilead and Vir Sign Up to $1.88 Billion Solid-Tumor Therapy Deal
Gilead Sciences and Vir Biotechnology have entered a collaboration and license agreement to discover and develop T-cell engager therapies for solid tumors. The...
Gilead expands lenacapavir access via PAHO, targeting rising Latin American HIV rates
Gilead Sciences partnered with the Pan American Health Organization (PAHO) to increase access to lenacapavir. This twice-yearly injectable drug provides...
🔴 Gilead Sciences is trading 4.38% down in after-hours trading with no credible company-specific explanation
Gilead Sciences is trading 4.38% down at $139.30 after falling from the August 28 regular-session close of $145.68, with no credible company-specific...
Gilead's Trodelvy Wins Expanded EU Approval for First-Line Breast Cancer
Gilead Sciences announced that the European Commission (EC) has expanded the marketing authorization for its cancer drug Trodelvy. The new approval is for...
🔴 Gilead Sciences is trading 4% down today as acquisition charges and valuation concerns trigger profit-taking
Gilead Sciences is trading 4% down at $129.81 as investors reassess the company's recent earnings performance, balancing strong top-line growth against...
Gilead's second quarter revenue grew 10% to $7.8B, beating estimates, but reported a larger-than-expected loss on acquisition charges.
Gilead Sciences reported second quarter 2026 revenue of $7.8 billion, a 10% increase year-over-year, driven by strong performance in its core business....
Gilead wins HIV drug lawsuit, court rejects duty to innovate rule
The California Supreme Court ruled in favor of Gilead Sciences, finding the company had no legal obligation to release newer HIV treatments sooner....
Gilead Sciences Inc Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
Gilead Sciences is expected to report Q2 2026 revenue of $7.40 billion and a consensus loss of $7.07 per share, with the stock currently trading at $130.26...
Gilead Nears EU Approval for Trodelvy, Cutting Progression Risk 35%
Gilead Sciences received a positive opinion from the European Medicines Agency’s expert panel for its drug Trodelvy. The Committee for Medicinal Products for...
🔴 Gilead Sciences drops after failed Phase 3 solid tumor trial
Gilead Sciences is trading at $129.30 (4.1% down) today following the announcement of a failed Phase 3 solid tumor clinical trial. • The decline also comes...
🟢 GILD is trading 3.5% up today as HSBC dismisses HIV generic competition fears
GILD is trading 3.5% up at $134.19 following a bullish upgrade from HSBC regarding the company's HIV franchise. • HSBC raised its rating on Gilead to Buy from...
Gilead Sciences Upgraded to Buy, HSBC Dismisses HIV Generic Fears
HSBC upgraded Gilead Sciences to Buy from Hold on Monday. The bank raised its price target for the stock to $155 from $133. Analysts believe the market is...
🟢 GILD is trading 3.1% up today after FDA approves Trodelvy for first-line breast cancer treatment
GILD is trading 3.1% up at $127.69 after the FDA approved its cancer drug Trodelvy for the first-line treatment of metastatic triple-negative breast cancer. •...
Gilead’s Trodelvy Wins FDA Approval for First-Line Breast Cancer, Expanding Market
Gilead Sciences received FDA approval for Trodelvy as a first-line treatment for metastatic triple-negative breast cancer (mTNBC). This approval transitions...
🔴 Gilead Sciences Inc is trading 2.0% down today in a consolidation move following recent Fed-driven volatility
Gilead Sciences Inc is trading 2.0% down today at $122.89 as the stock undergoes an idiosyncratic consolidation following recent gains and broader market...
🔴 Gilead Sciences Inc is trading 2.1% down today on profit-taking amid broader market weakness after the Fed decision
Gilead Sciences Inc is trading at $124.55 (2.1% down) as investors lock in profits following yesterday's rally, pressured by a broader market selloff after the...
🟢 Gilead Sciences Inc is trading 2.02% up today after FDA accepts its once-weekly HIV PrEP filing for Yeztugo
Gilead Sciences Inc is trading at $126.81 (+2.02%) today after the FDA accepted its supplemental New Drug Application (sNDA) for Yeztugo (lenacapavir) as a...
Gilead Seeks FDA Approval for First Once-Weekly Oral HIV PrEP
Gilead Sciences announced the FDA accepted its supplemental New Drug Application for Yeztugo (lenacapavir). The application covers an investigational 300-mg...
🟢 Gilead Sciences Inc is trading 4.6% up today on risk-on market tone and healthcare sector strength
Gilead Sciences Inc is trading 4.6% up today at $127.06 as the stock recovers from a recent two-day pullback amid a broader risk-on market tone and renewed...